德国制药业批美滥施关税造成负面影响

Core Points - The U.S. government has announced a 100% tariff on all imported brand-name or patented drugs starting October 1, which will severely impact the German and European pharmaceutical industries and negatively affect U.S.-EU trade relations [1] - The German Chemical Industry Association expressed deep concern over the U.S. measures, indicating that it marks a new low in U.S.-EU trade relations [1] - The German Pharmaceutical Industry Association highlighted that the new tariffs will disrupt international supply chains, increase drug production costs, and threaten the supply of medications for patients in both the U.S. and Europe [1] Industry Impact - The German Pharmaceutical Industry Association stated that the U.S. tariffs represent a "brutal and problematic" approach, signaling a dangerous message to the German pharmaceutical sector [1] - The U.S. is a crucial export market for the German pharmaceutical industry, with exports expected to exceed €27 billion in 2024, accounting for about one-quarter of Germany's total pharmaceutical exports [1]